{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:38:56Z","timestamp":1788881936144,"version":"build-2803163510"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It is widely recognized that pharmaceutical marketing contributed to the ongoing US opioid epidemic, but less is understood about how the opioid industry used scientific evidence to generate product demand, shape opioid regulation, and change clinician behavior. In this qualitative study, we characterize select scientific articles used by industry to support safety and effectiveness claims and use a novel database, the Opioid Industry Documents Archive, to determine notable elements of industry and non-industry documents citing the scientific articles to advance each claim. We found that 15 scientific articles were collectively mentioned in 3666 documents supporting 5 common, inaccurate claims: opioids are effective for treatment of chronic, non-cancer pain; opioids are \u201crarely\u201d addictive; \u201cpseudo-addiction\u201d is due to inadequate pain management; no opioid dose is too high; and screening tools can identify those at risk of developing addiction. The articles contributed to the eventual normalization of these claims by symbolically associating the claims with scientific evidence, building credibility, expanding and diversifying audiences and the parties asserting the claims, and obfuscating conflicts of interest. These findings have implications for regulators of industry products and corporate activity and can inform efforts to prevent similar public health crises.<\/jats:p>","DOI":"10.1093\/haschl\/qxae119","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:49:37Z","timestamp":1729784977000},"source":"Crossref","is-referenced-by-count":8,"title":["The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness"],"prefix":"10.1093","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-6414","authenticated-orcid":false,"given":"Ravi","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Johns Hopkins University School of Medicine , Baltimore, MD, 21287 ,","place":["United States"]},{"name":"Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chernesky","sequence":"additional","affiliation":[{"name":"Department of the History of Medicine and Center for Medical Humanities and Social Medicine, Johns Hopkins University School of Medicine , Baltimore, MD, 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lembke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine , Stanford, CA, 94304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8558-7733","authenticated-orcid":false,"given":"David","family":"Michaels","sequence":"additional","affiliation":[{"name":"Milken Institute School of Public Health, George Washington University , Washington, DC, 20037 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4235-1821","authenticated-orcid":false,"given":"Cecilia","family":"Tomori","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Nursing and Bloomberg School of Public Health, Johns Hopkins University , Baltimore, MD, 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Johns Hopkins University School of Medicine , Baltimore, MD, 21287 ,","place":["United States"]},{"name":"Department of the History of Medicine and Center for Medical Humanities and Social Medicine, Johns Hopkins University School of Medicine , Baltimore, MD, 21205 ,","place":["United States"]},{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD, 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-2986","authenticated-orcid":false,"given":"G Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD, 21205 ,","place":["United States"]},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD, 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-9810","authenticated-orcid":false,"given":"Adam D","family":"Koon","sequence":"additional","affiliation":[{"name":"School of Health, Department of Global Health, Georgetown University , Washington, DC, 20057 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"2","key":"2024102415492030800_qxae119-B1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee","year":"2009","journal-title":"Am J Public Health"},{"issue":"3","key":"2024102415492030800_qxae119-B2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.mayocp.2017.12.020","article-title":"How good intentions contributed to bad outcomes: the opioid crisis","volume":"93","author":"Rummans","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2024102415492030800_qxae119-B3","author":"Facher"},{"issue":"2","key":"2024102415492030800_qxae119-B4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamainternmed.2019.5459","article-title":"Evaluation of the extended-release\/long-acting opioid prescribing risk evaluation and mitigation strategy program by the US Food and Drug Administration: a review","volume":"180","author":"Heyward","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2024102415492030800_qxae119-B5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/amj.2023.9","article-title":"Opioid litigation: lessons learned from a retail pharmacy settlement","volume":"48","author":"Gonick","year":"2022","journal-title":"Am J Law Med"},{"issue":"24","key":"2024102415492030800_qxae119-B6","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMp1710756","article-title":"Drug companies\u2019 liability for the opioid epidemic","volume":"377","author":"Haffajee","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2024102415492030800_qxae119-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1257\/aer.20210357","article-title":"Retail pharmacies and drug diversion during the opioid epidemic","volume":"113","author":"Janssen","year":"2023","journal-title":"Am Econ Rev"},{"issue":"2","key":"2024102415492030800_qxae119-B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJM198001103020221","article-title":"Addiction rare in patients treated with narcotics","volume":"302","author":"Porter","year":"1980","journal-title":"N Engl J Med"},{"key":"2024102415492030800_qxae119-B9","author":"Jones"},{"issue":"10383","key":"2024102415492030800_qxae119-B10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0140-6736(23)00013-2","article-title":"Defining and conceptualising the commercial determinants of health","volume":"401","author":"Gilmore","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"2024102415492030800_qxae119-B11","doi-asserted-by":"crossref","first-page":"e232795","DOI":"10.1001\/jamahealthforum.2023.2795","article-title":"Understanding the US health care industry as a commercial determinant of health","volume":"4","author":"Galea","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"7377","key":"2024102415492030800_qxae119-B12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/bmj.325.7377.1413","article-title":"How the tobacco industry responded to an influential study of the health effects of secondhand smoke","volume":"325","author":"Hong","year":"2002","journal-title":"BMJ"},{"issue":"Suppl 1","key":"2024102415492030800_qxae119-B13","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.2105\/AJPH.2004.043059","article-title":"Manufacturing uncertainty: contested science and the protection of the public's health and environment","volume":"95","author":"Michaels","year":"2005","journal-title":"Am J Public Health"},{"key":"2024102415492030800_qxae119-B14","volume-title":"Merchants of Doubt: How a Handful of Scientists Obscured the Truth on Issues from Tobacco Smoke to Global Warming","author":"Oreskes","year":"2010"},{"key":"2024102415492030800_qxae119-B15","volume-title":"The Triumph of Doubt: Dark Money and the Science of Deception","author":"Michaels","year":"2020"},{"issue":"1","key":"2024102415492030800_qxae119-B16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12940-021-00723-0","article-title":"The science of spin: targeted strategies to manufacture doubt with detrimental effects on environmental and public health","volume":"20","author":"Goldberg","year":"2021","journal-title":"Environ Health"},{"issue":"1","key":"2024102415492030800_qxae119-B17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/add.13048","article-title":"How does the alcohol industry attempt to influence marketing regulations? A systematic review","volume":"111","author":"Savell","year":"2016","journal-title":"Addiction"},{"issue":"9","key":"2024102415492030800_qxae119-B18","doi-asserted-by":"crossref","first-page":"e1002125","DOI":"10.1371\/journal.pmed.1002125","article-title":"The policy dystopia model: an interpretive analysis of tobacco industry political activity","volume":"13","author":"Ulucanlar","year":"2016","journal-title":"PLoS Med"},{"key":"2024102415492030800_qxae119-B19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.publhealth.24.100901.140813","article-title":"Implications of the tobacco industry documents for public health and policy","volume":"24","author":"Bero","year":"2003","journal-title":"Annu Rev Public Health"},{"key":"2024102415492030800_qxae119-B20","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.drugpo.2023.103997","article-title":"The opioid industry document archive: new directions in research on corporate political strategy","volume":"114","author":"MacKenzie","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"12","key":"2024102415492030800_qxae119-B21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1056\/NEJMp1914257","article-title":"Opioid prescribing in the midst of crisis\u2014myths and realities","volume":"382","author":"Barnett","year":"2020","journal-title":"N Engl J Med"},{"key":"2024102415492030800_qxae119-B22","volume-title":"Empire of Pain: the Secret History of the Sackler Dynasty","author":"Keefe","year":"2021"},{"key":"2024102415492030800_qxae119-B23","author":"University of California, San Francisco"},{"issue":"8","key":"2024102415492030800_qxae119-B24","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2105\/AJPH.2022.306951","article-title":"The opioid industry documents archive: a living digital repository","volume":"112","author":"Caleb Alexander","year":"2022","journal-title":"Am J Public Health"},{"key":"2024102415492030800_qxae119-B25","volume-title":"Interpretive Research Design: Concepts and Processes","author":"Schwartz-Shea","year":"2012"},{"issue":"Suppl 2","key":"2024102415492030800_qxae119-B26","doi-asserted-by":"crossref","first-page":"ii40","DOI":"10.1136\/tobaccocontrol-2016-053212","article-title":"Tobacco industry use of flavourings to promote smokeless tobacco products","volume":"25","author":"Kostygina","year":"2016","journal-title":"Tob Control"},{"issue":"8","key":"2024102415492030800_qxae119-B27","doi-asserted-by":"crossref","first-page":"e2228088","DOI":"10.1001\/jamanetworkopen.2022.28088","article-title":"Content analysis of the corporate social responsibility practices of 9 major cannabis companies in Canada and the US","volume":"5","author":"Wakefield","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"15","key":"2024102415492030800_qxae119-B28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jama.299.15.1800","article-title":"Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation","volume":"299","author":"Ross","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"2024102415492030800_qxae119-B29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1215\/03616878-11186127","article-title":"Inside \u201coperation change agent\u201d: Mallinckrodt's plan for capturing the opioid market","volume":"49","author":"Klein","year":"2024","journal-title":"J Health Polit Policy Law"},{"key":"2024102415492030800_qxae119-B30","volume-title":"The Discovery of Grounded Theory: Strategies for Qualitative Research","author":"Glaser","year":"1967"},{"issue":"12","key":"2024102415492030800_qxae119-B31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/0277-9536(84)90027-3","article-title":"Long-term use of narcotic analgesics in chronic pain","volume":"19","author":"France","year":"1984","journal-title":"Soc Sci Med"},{"issue":"2","key":"2024102415492030800_qxae119-B32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0304-3959(86)90091-6","article-title":"Chronic use of opioid analgesics in non-malignant pain: report of 38 cases","volume":"25","author":"Portenoy","year":"1986","journal-title":"Pain"},{"issue":"3","key":"2024102415492030800_qxae119-B33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-3959(82)90016-1","article-title":"Management of pain during debridement: a survey of U.S. burn units","volume":"13","author":"Perry","year":"1982","journal-title":"Pain"},{"issue":"2","key":"2024102415492030800_qxae119-B34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00002508-199206000-00003","article-title":"Drug abuse, dependence, and addiction in chronic pain patients","volume":"8","author":"Fishbain","year":"1992","journal-title":"Clin J Pain"},{"issue":"13","key":"2024102415492030800_qxae119-B35","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jama.283.13.1710","article-title":"Trends in medical use and abuse of opioid analgesics","volume":"283","author":"Joranson","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"2024102415492030800_qxae119-B36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1526-4637.2007.00370.x","article-title":"What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse\/addiction and\/or aberrant drug-related behaviors? A structured evidence-based review","volume":"9","author":"Fishbain","year":"2008","journal-title":"Pain Med"},{"issue":"3","key":"2024102415492030800_qxae119-B37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0304-3959(89)90097-3","article-title":"Opioid pseudoaddiction\u2014an iatrogenic syndrome","volume":"36","author":"Weissman","year":"1989","journal-title":"Pain"},{"issue":"9171","key":"2024102415492030800_qxae119-B38","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0140-6736(99)03528-X","article-title":"Opioids in pain management","volume":"353","author":"McQuay","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"2024102415492030800_qxae119-B39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1526-4637.2002.02013.x","article-title":"Medico-legal rounds: medico-legal issues and breaches of \u201cstandards of medical care\u201d in opioid tapering for alleged opioid addiction","volume":"3","author":"Fishbain","year":"2002","journal-title":"Pain Med"},{"issue":"3","key":"2024102415492030800_qxae119-B40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90025-9","article-title":"The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions","volume":"43","author":"Portenoy","year":"1990","journal-title":"Pain"},{"issue":"9","key":"2024102415492030800_qxae119-B41","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2011.166","article-title":"A true believer's flawed analysis","volume":"171","author":"Foley","year":"2011","journal-title":"Arch Intern Med"},{"issue":"6","key":"2024102415492030800_qxae119-B42","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"issue":"9","key":"2024102415492030800_qxae119-B43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpain.2006.03.001","article-title":"The DIRE score: predicting outcomes of opioid prescribing for chronic pain","volume":"7","author":"Belgrade","year":"2006","journal-title":"J Pain"},{"issue":"2","key":"2024102415492030800_qxae119-B44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1533-2500.2006.00065.x","article-title":"An opioid screening instrument: long-term evaluation of the utility of the pain medication questionnaire by Holmes et al","volume":"6","author":"Passik","year":"2006","journal-title":"Pain Pract"},{"key":"2024102415492030800_qxae119-B45"},{"key":"2024102415492030800_qxae119-B46","author":"Riddle"},{"key":"2024102415492030800_qxae119-B47","author":"Bronwyn"},{"issue":"7","key":"2024102415492030800_qxae119-B48","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/pm\/pnx332","article-title":"Re-assessing the validity of the opioid risk tool in a tertiary academic pain management center population","volume":"19","author":"Clark","year":"2018","journal-title":"Pain Med"},{"key":"2024102415492030800_qxae119-B49","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCERTA218","volume-title":"The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain","author":"Chou","year":"2014"},{"key":"2024102415492030800_qxae119-B50","author":"Lozier"},{"key":"2024102415492030800_qxae119-B51"},{"key":"2024102415492030800_qxae119-B52","author":"Webster"},{"key":"2024102415492030800_qxae119-B53","author":"District Court of Cleveland County, State of Oklahoma"},{"issue":"22","key":"2024102415492030800_qxae119-B54","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1056\/NEJMc1700150","article-title":"A 1980 letter on the risk of opioid addiction","volume":"376","author":"Leung","year":"2017","journal-title":"N Engl J Med"},{"key":"2024102415492030800_qxae119-B55","first-page":"189","volume-title":"Researching Corporations and Global Health Governance: An Interdisciplinary Guide","author":"MacKenzie","year":"2016"},{"issue":"Suppl 2","key":"2024102415492030800_qxae119-B56","doi-asserted-by":"crossref","first-page":"ii8","DOI":"10.1136\/tc.2010.041921","article-title":"Tobacco documents research methodology","volume":"20","author":"Anderson","year":"2011","journal-title":"Tob Control"},{"key":"2024102415492030800_qxae119-B57","doi-asserted-by":"crossref","first-page":"q1208","DOI":"10.1136\/bmj.q1208","article-title":"How an opioid giant deployed a playbook for moulding doctors\u2019 minds","volume":"385","author":"Sismondo","year":"2024","journal-title":"BMJ"},{"key":"2024102415492030800_qxae119-B58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1332\/174426421X16856230946027","article-title":"Issues arising from the study design, conduct, and promotion of clinical trials funded by opioid manufacturers: a review of internal pharmaceutical industry documents","volume":"19","author":"Gac","year":"2023","journal-title":"Evid Policy"},{"key":"2024102415492030800_qxae119-B59","doi-asserted-by":"crossref","first-page":"1327939","DOI":"10.3389\/fmed.2024.1327939","article-title":"Promoting opioids, a story about how to influence medical science and opinions","volume":"11","author":"Bernisson","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2024102415492030800_qxae119-B60","doi-asserted-by":"crossref","first-page":"e076797","DOI":"10.1136\/bmj-2023-076797","article-title":"Tackling the excesses of pharmaceutical marketing and promotion","volume":"385","author":"Gupta","year":"2024","journal-title":"BMJ"},{"issue":"2S","key":"2024102415492030800_qxae119-B61","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.36076\/ppj.2017.s151","article-title":"Educational outreach to opioid prescribers: the case for academic detailing","volume":"20","author":"Trotter Davis","year":"2017","journal-title":"Pain Physician"},{"key":"2024102415492030800_qxae119-B62"},{"issue":"7","key":"2024102415492030800_qxae119-B63","doi-asserted-by":"crossref","first-page":"e1067","DOI":"10.1016\/S2214-109X(22)00185-1","article-title":"The public health playbook: ideas for challenging the corporate playbook","volume":"10","author":"Lacy-Nichols","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2024102415492030800_qxae119-B64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2105\/AJPH.2011.300292","article-title":"Inventing conflicts of interest: a history of tobacco industry tactics","volume":"102","author":"Brandt","year":"2012","journal-title":"Am J Public Health"},{"key":"2024102415492030800_qxae119-B65","author":"Tobacco Tactics"},{"issue":"11","key":"2024102415492030800_qxae119-B66","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2105\/AJPH.91.11.1749","article-title":"Constructing \u201csound science\u201d and \u201cgood epidemiology\u201d: tobacco, lawyers, and public relations firms","volume":"91","author":"Ong","year":"2001","journal-title":"Am J Public Health"},{"key":"2024102415492030800_qxae119-B67","volume-title":"The Cigarette Papers","author":"Glantz","year":"1996"},{"issue":"12","key":"2024102415492030800_qxae119-B68","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.2105\/AJPH.2021.306491","article-title":"Defining priorities for action and research on the commercial determinants of health: a conceptual review","volume":"111","author":"Freudenberg","year":"2021","journal-title":"Am J Public Health"},{"issue":"3","key":"2024102415492030800_qxae119-B69","doi-asserted-by":"crossref","first-page":"e12011","DOI":"10.1002\/cesm.12011","article-title":"What did the scientific literature learn from internal company documents in the pharmaceutical industry? A scoping review","volume":"1","author":"Gagnon","year":"2023","journal-title":"Cochrane Evid Synthesis Methods"},{"key":"2024102415492030800_qxae119-B70","first-page":"105","article-title":"Corporate manipulation of research: strategies are similar across five industries","volume":"21","author":"White","year":"2010","journal-title":"Stanford Law and Policy Review"},{"key":"2024102415492030800_qxae119-B71","doi-asserted-by":"crossref","first-page":"117158","DOI":"10.1016\/j.socscimed.2024.117158","article-title":"The role of metaphor in the corporate political strategies of health harming industries: comparing the concept of balance in the gambling and opioid industry discourses","volume":"356","author":"van Schalkwyk","year":"2024","journal-title":"Soc Sci Med"},{"issue":"6","key":"2024102415492030800_qxae119-B72","doi-asserted-by":"crossref","first-page":"e0253272","DOI":"10.1371\/journal.pone.0253272","article-title":"The science for profit model-how and why corporations influence science and the use of science in policy and practice","volume":"16","author":"Legg","year":"2021","journal-title":"PLoS One"},{"issue":"10324","key":"2024102415492030800_qxae119-B73","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","article-title":"Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission","volume":"399","author":"Humphreys","year":"2022","journal-title":"Lancet"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/10\/qxae119\/60013657\/qxae119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/10\/qxae119\/60013657\/qxae119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:49:52Z","timestamp":1729784992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxae119\/7831114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxae119","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10]]},"article-number":"qxae119"}}